Industry reports
Editor highlights

Search inside this page

Free Market Research Guides to Download

Biological Therapy Analysis & Statistics, April 2014

You might be interested in: stem cell, cell therapy, tissue engineering, more »

» Purchase Premium Reports

1-30 of about 400 reports
Analytical Tool - Cancer Immunotherapy

Analytical Tool - Cancer Immunotherapy

  • $ 8 175
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool- Cancer Immunotherapy" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in immunotherapy drug development for the treatment of cancer. It ...

  • Industries : Biological Therapy
Analytical Tool - Cancer Therapeutic Antibodies

Analytical Tool - Cancer Therapeutic Antibodies

  • $ 5 924
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. ...

  • Industries : Biological Therapy
Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020

Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 - 2020

  • $ 4 515
  • Industry report
  • January 2014
  • by Allied Market Research

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective ...

  • Industries : Biological Therapy
  • Countries : World
Immunotherapy in Oncology Drug Pipeline Update 2014

Immunotherapy in Oncology Drug Pipeline Update 2014

  • $ 3 675
  • Industry report
  • March 2014
  • by Bioseeker

Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the ...

  • Industries : Biological Therapy
Immunotherapy in Oncology: Drug Pathway Analyzer 2014

Immunotherapy in Oncology: Drug Pathway Analyzer 2014

  • $ 3 675
  • Industry report
  • March 2014
  • by Bioseeker

Extra value: One year of free online updates included with this product There are today at least 811 immunotherapy drugs known to affect more than 234 specific intracellular signaling pathways for the ...

  • Industries : Biological Therapy
Regenerative medicine and Stem cells Partnering Terms and Agreements

Regenerative medicine and Stem cells Partnering Terms and Agreements

  • $ 2 995
  • Industry report
  • March 2014
  • by Currentpartnering

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals ...

  • Industries : Biological Therapy
Trastuzumab: Pipeline™ Developer: Patent Report

Trastuzumab: Pipeline™ Developer: Patent Report

  • $ 2 529
  • Industry report
  • March 2014
  • by GenericsWeb

0

  • Industries : Biological Therapy
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

The androgen receptor signaling pathway activates the SMAD signaling module. There are today 327 companies plus partners developing 426 Androgen Receptor drugs in 1397 developmental projects in cancer. ...

  • Industries : Biological Therapy
Notch Signaling Pathway in Oncology Drug Pipeline Update 2014

Notch Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

Aberrant Notch signaling has been linked to a number of malignancies including leukemias, lymphomas and carcinomas of the breast, skin, lung, cervix and kidneys. There are today 249 companies plus partners ...

  • Industries : Biological Therapy
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

Activation of the B cell receptor involves phosphorylation of the cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) present in Ig alpha and beta. This leads to activation of several non-recepto ...

  • Industries : Biological Therapy
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

Stimulation of the T cell receptor leads to the activation of NFkB and NFAT signaling modules which play a key role in T cell receptor signaling. There are today 242 companies plus partners developing ...

  • Industries : Biological Therapy
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014

Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

Cytokines are soluble extracellular proteins or glycoproteins that are crucial intercellular regulators and mobilizers of cells engaged in innate as well as adaptive inflammatory host defenses, cell growth, ...

  • Industries : Biological Therapy
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014

EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

The EGFR1 signaling pathway activates the Ras/Raf/MAPK signaling modules. There are today 365 companies plus partners developing 620 EGFR1 pathway targeting drugs in 2313 developmental projects in cancer. ...

  • Industries : Biological Therapy
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

The TGF-beta receptor signaling pathway activates the MAPK/SMAD signaling modules. There are today 288 companies plus partners developing 403 TGF-beta receptor pathway targeting drugs in 1356 developmental ...

  • Industries : Biological Therapy
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014

Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

Aberrant activation of the Hedgehog pathway has been associated with a number of human malignancies including carcinoma of lung, esophagus, pancreas and prostate. There are today 119 companies plus partners ...

  • Industries : Biological Therapy
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014

TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

The TNF-alfa signaling pathway stimulates the MAPK signaling module and activates NFkB. There are today 359 companies plus partners developing 531 TNF-alpha pathway targeting drugs in 1960 developmental ...

  • Industries : Biological Therapy
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014

Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors of breast, colon, pancreas, liver and bone. There are today 178 companies plus partners ...

  • Industries : Biological Therapy
Cancer Stem Cells Drug Pipeline Update 2014

Cancer Stem Cells Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs which ...

  • Industries : Biological Therapy
Gene Therapy in Oncology Drug Pipeline Update 2014

Gene Therapy in Oncology Drug Pipeline Update 2014

  • $ 2 249
  • Industry report
  • March 2014
  • by Bioseeker

There are today 121 companies plus partners developing 109 gene therapy drugs in 278 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs ...

  • Industries : Biological Therapy
Cell Therapy Deals and Alliances of 2013

Cell Therapy Deals and Alliances of 2013

  • $ 1 495
  • Industry report
  • March 2014
  • by Currentpartnering

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Cell Therapy Deals ...

  • Industries : Biological Therapy
Rituximab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Rituximab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 ...

  • Industries : Biological Therapy
  • Countries : World
Trastuzumab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Trastuzumab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 ...

  • Industries : Biological Therapy
  • Countries : World
Filgrastim - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Filgrastim - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 ...

  • Industries : Biological Therapy
  • Countries : World
Bevacizumab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Bevacizumab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 ...

  • Industries : Biological Therapy
  • Countries : World
Epoetin alfa - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Epoetin alfa - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 ...

  • Industries : Biological Therapy
  • Countries : World
Imiquimod - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Imiquimod - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 ...

  • Industries : Biological Therapy
  • Countries : World
Cetuximab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

Cetuximab - Key patent, SPC, and data exclusivity expiry (44 countries coverage)

  • $ 1 105
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 ...

  • Industries : Biological Therapy
  • Countries : World
ID Signaling Pathway in Oncology Drug Pipeline Update 2014

ID Signaling Pathway in Oncology Drug Pipeline Update 2014

  • $ 749
  • Industry report
  • March 2014
  • by Bioseeker

Inhibitor of DNA binding (ID) proteins are members of the helix-loop-helix (HLH) family of proteins which lack a DNA binding domain themselves but bind to other family members inhibiting their DNA binding ...

  • Industries : Biological Therapy
Epoetin alfa - Key patent, SPC, and data exclusivity expiry (7 country coverage)

Epoetin alfa - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • $ 460
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries ...

  • Industries : Biological Therapy
  • Countries : World
Imiquimod - Key patent, SPC, and data exclusivity expiry (7 country coverage)

Imiquimod - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • $ 460
  • Industry report
  • March 2014
  • by GenericsWeb

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries ...

  • Industries : Biological Therapy
  • Countries : World

» View Public Reports

About 900 reports

Cell Culture Business (cell culture, cell therapy) in Thailand and The United States

  • Industry report
  • March 2014
  • 7 pages
  • by Research Paper

... cultured cells selected for high production of secondary metabolites (dicosmo and misawa, 1995). One way to increase the production level of secondary metabolites is by elicitation, which ...


» Read our Company Profiles

35 Companies

GlaxoSmithKline P.L.C.

United States

Bioheart Inc.

United States

StemCells Inc.

United States

Geron Corp.

United States

Osiris Therapeutics Inc.

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.